Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BRIEF-Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus infection

By: Reuters: Company News
* Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus (HDV) infection
Related Stocks:
Eiger Biopharma
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.